Company closed PIPE financing with gross proceeds of up to $175 million, including the possible exercise of warrants, from long-term global investors. Proceeds are expected to fund the Company through 2027, including completion of the ongoing Phase 1b clinical trial in Alzheimer's disease (AD).
PRECISE-AD Phase 1b trial is fully enrolled and progressing on s...
Get updates from ProMIS Neurosciences, Inc. (PMN) Press Releases via email, on your phone or read them on follow.it on your own custom news page.
You can filter the news from ProMIS Neurosciences, Inc. (PMN) Press Releases that get delivered to you using tags or topics or you can opt for all of them. Unsubscription is also very simple.
See the latest news from ProMIS Neurosciences, Inc. (PMN) Press Releases below.
Site title: ProMIS Neurosciences, Inc. (PMN)